Skip to content

Study · Measured the body's own peptide · 1993

2 results

Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration.

Edvinsson L, Minthon L, Ekman R, Gustafson L

Dementia (Basel, Switzerland)1 May 1993Cited by 45 (Europe PMC)

PMID8401787 (opens in a new tab)DOI10.1159/000107318 (opens in a new tab)PepBankPUB-08401787
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with frontal lobe degeneration, cerebrospinal fluid DSIP levels were the same as in controls.

    In plain wordsIn people with frontal lobe dementia, the body's own DSIP levels in spinal fluid were the same as in controls.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    No significant changeCSF DSIP in frontal lobe degeneration
    Study

    n = 41

    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    The levels of DSIP in FLD were the same as in controls.
    1 context sentence
    Summary · context
    In a clinical material of 80 patients with either of the two forms of dementia (DAT = 39, FLD = 41) we have studied the levels of neuropeptides in the cerebrospinal fluid (CSF) in order to find biochemical markers for CNS affection.

    This result measures the body's own Delta sleep-inducing peptide (DSIP). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In patients with dementia of Alzheimer type, cerebrospinal fluid levels of DSIP were strongly reduced, in this group only.

    In plain wordsIn people with Alzheimer-type dementia, the body's own DSIP levels in spinal fluid were strongly lower, but not in frontal lobe dementia.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    DecreaseCSF DSIP in Alzheimer-type dementia
    Study

    n = 39

    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    Most notably there was a strong reduction in the levels of delta sleep inducing peptide (DSIP) in DAT cases only.
    1 context sentence
    Summary · context
    In a clinical material of 80 patients with either of the two forms of dementia (DAT = 39, FLD = 41) we have studied the levels of neuropeptides in the cerebrospinal fluid (CSF) in order to find biochemical markers for CNS affection.

    This result measures the body's own Delta sleep-inducing peptide (DSIP). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.